GlassScriptPhysician profile
Morgan L Zebulske
NPI 1164031720
$8,680.85
in general payments reported to CMS, 2019-2025
25 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,161 · 2023: $2,332 · 2024: $2,764 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,916 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,916.07 |
| Education | $321.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,463.37 | 2021-2025 | |
| Genzyme Corporation | $1,098.72 | 2021-2025 | |
| Janssen Biotech, INC. | $784.77 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $751.40 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $647.28 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $599.98 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $540.66 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $533.98 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $387.58 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $270.20 | 2021-2025 | Opzelura |
| Ucb, INC. | $266.17 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $257.98 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $256.10 | 2023-2025 | Zoryve |
| Amgen INC. | $220.87 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $178.99 | 2023-2024 | Aklief, Oracea |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $96.76 | 2023-2024 | Vtama |
| Epi Health, LLC | $77.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.49 | 2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.74 | 2024-2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $46.11 | 2023 | Ycanth |
| Sandoz INC. | $43.24 | 2024 | Hyrimoz |
| Botanix Sb INC | $23.52 | 2025 | Sofdra |
| Smith+Nephew, INC. | $17.11 | 2023 | Grafix Pl, Grafix, Stravix |
| Almirall LLC | $16.15 | 2023 | Klisyri |
| Mayne Pharma Commercial LLC | $6.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Zebulske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.